

Category : Study conduct-All studies (Government funded/NGO Regulatory)
Title : Serious Adverse Event (SAE) Monitoring, Recording and Reporting
SOP No/ Version No. : 15/08
Date first effective: 01 Jan 2026 Review date: 31 Dec 2026

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

Category: Study conduct-All studies (Government funded/NGO
funded/Regulatory)
Title: Serious Adverse Event (SAE) Monitoring, Recording and Reporting.
SOP No/ Version No.: 15/08 Total pages: 08
Date first effective: 01 Jan 2026 Next Review date: 31 Dec 2026

Version: 08

Author:

1) Dr. Shiva Krishna Rao.T
1st Year DM Resident

Shiva Krishna Rao.T
1/Jan/2026

2) Dr. Shital Bendkhale
Project Scientist- II

Sendell
1/Jan/2026

Signature with date

Reviewer:

Dr. Roopa Parida
Assistant Professor

Signature with date

Roopa Parida
01/Jan/26

Approved by:

Dr. Nithya Gogtay
Professor and Head

Signature with date

Nithya Gogtay
1.1.26

Confidential

Dr Nithya Gogtay
Professor & Head
Department of Clinical Pharmacology
1st Floor, MS Building
Seth GS Medical College & KEM Hospital
Parel, Mumbai 400 012

Page 1 of 9

Category : Study conduct-All studies (Government funded/NGO Regulatory)
Title : Serious Adverse Event (SAE) Monitoring, Recording and Reporting
SOP No/ Version No. : 15/08
Date first effective: 01 Jan 2026 **Review date:** 31 Dec 2026

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

Table of Contents

No.	Contents	Page No.
1	Purpose	3
2	Scope	3
3	Responsibility	3
4	Applicable rules, regulations and guidelines	3
5	Reference to other applicable SOPs	3
6	Detailed instructions	3
7	Appendices	5

W 1-1-26
Dr Nithya Gogtay
Professor & Head
Department of Clinical Pharmacology
1st Floor, MS Building
Seth GS Medical College & KEM Hospital
Parel, Mumbai 400 012

Category : Study conduct-All studies (Government funded/NGO Regulatory)
Title : Serious Adverse Event (SAE) Monitoring, Recording and Reporting
SOP No/ Version No. : 15/08
Date first effective: 01 Jan 2026 **Review date:** 31 Dec 2026

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

1. Purpose

This standard operating procedure (SOP) describes the responsibilities of the study team for monitoring, recording and reporting a serious adverse event (SAE) from the time it is identified until all follow-up activities associated with its resolution have been completed.

2. Scope

This SOP applies to all clinical studies involving human participants.

3. Responsibilities

Principal investigator, Co-investigator, Study Coordinator or any other appropriately qualified staff in the team, as delegated by the Principal Investigator, will be responsible for monitoring, recording and reporting serious adverse events.

4. Applicable rules, regulations and guidelines

- National Ethical Guidelines for Biomedical and Health Research involving Human Participants (2017), https://ethics.ncdirindia.org/ICMR_Ethical_Guidelines.aspx, last accessed on 12th March 2026.
- New Drugs and Clinical Trials Rules (2019), <https://cdsco.gov.in/opencms/opencms/en/Acts-and-rules/New-Drugs/>, last accessed on 12th March 2026.
- ICH HARMONISED GUIDELINE GOOD CLINICAL PRACTICE (GCP) E6(R3), https://database.ich.org/sites/default/files/ICH_E6%28R3%29_DraftGuideline_2023_0519.pdf, last accessed on 12th March 2026.
- India GCP guidelines (Draft, September 2024), https://ethics.ncdirindia.org/asset/pdf/Indian_GCP_guideline.pdf, last accessed on 12th March 2026.
- National Ethical Guidelines for Biomedical Research Involving Children. https://ethics.ncdirindia.org//asset/pdf/National_Ethical_Guidelines_for_BioMedical_Research_Involving_Children.pdf last accessed on 12th March 2026.

Confidential

le *1-1-26*
Dr Nithya Gogtay
Professor & Head
Department of Clinical Pharmacology
1st Floor, MS Building
Seth GS Medical College & KEM Hospital
Parel, Mumbai 400 012

Page 3 of 9

Category : Study conduct-All studies (Government funded/NGO Regulatory)
Title : Serious Adverse Event (SAE) Monitoring, Recording and Reporting
SOP No/ Version No. : 15/08
Date first effective: 01 Jan 2026 Review date: 31 Dec 2026

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

- Standard-Operating-Procedures of Institutional Ethics Committee, Seth GS Medical College and KEM Hospital, Mumbai
https://www.kem.edu/wp-content/uploads/2025/03/SOPs_V7_effective_from_9th_Dec_2024_Seth_GSMC_&_KEMH_Mumbai.pdf V7-effective-from-9th-Dec-2024_.pdf (last accessed 10th Dec, 2025)

5. Reference to other applicable SOPs

- SOP No/ Version No 03/05: Responsibilities of the Study Team
- SOP No/ Version No 14/05: Adverse event monitoring, recording and reporting
- SOP No/ Version No 21/07: Contact and communication with sponsor
- Addendum to SOP for SAE Reporting

6. Detailed Instructions:

➤ Identify SAE

A Serious Adverse Event (SAE) is defined as
Any untoward medical occurrence that at any dose:

- Results in death,
- Is life-threatening,
- Requires inpatient hospitalization or prolongation of existing hospitalization,
- Results in persistent or significant disability/incapacity, or
- Is a congenital anomaly / birth defect

ICH E6 (R3) EWG Draft Guidelines dated 19th April, 2021.

- Is a significant medical event

I. Medical management of an SAE

1.1 Appropriate medical management of an SAE by referring to the appropriate collaborating (or, any other as applicable) department in the institute.

Dr Nithya Gogtay
Professor & Head
Department of Clinical Pharmacology
1st Floor, MS Building
Seth GS Medical College & KEM Hospital
Parel, Mumbai 400 012

Category : Study conduct-All studies (Government funded/NGO Regulatory)
Title : Serious Adverse Event (SAE) Monitoring, Recording and Reporting
SOP No/ Version No. : 15/08
Date first effective: 01 Jan 2026 **Review date:** 31 Dec 2026

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

Supportive measures should be immediately used as appropriate and are directed toward participant safety and well-being.

1.2 Participant will be followed up till complete resolution.

II. Documentation of an SAE

2.1 Document the nature of the SAE, which includes onset, duration, progress, management and outcome in the participant's source document/s.

2.2 Relatedness of the SAE to the clinical trial must be assessed by the PI and reported in the SAE form (Appendix 1 and 2)

2.3 The SAE reporting form of the department (See Appendix 1) and the SAE assessment form along checklist of the IEC (see Appendix 2) should be used for documentation in case of academic studies.

2.4 The SAE assessment form and checklist of the IEC (see Appendix 2) and SAE form provided by sponsors (if any) have to be filled in case of pharma sponsored studies.

2.5 In case the sponsor does not have a form then the SAE reporting form of the department (Appendix I) should be used for documentation.

2.6 Complete documentation should be done in the source documents and case record forms (CRFs).

III. Reporting of an SAE

3.1 Inform the Sponsor, Licensing Authority and Chairperson of Ethics Committee within 24 hours using the SAE reporting form (Appendix 3).

3.2 For an SAE (causing Death/ other than death): PI have to send a detailed report (after due analysis) within 14 days of the occurrence of the SAE (death) to the IEC, Head of the Institution and Licensing Authority (Appendix 3).

3.3 SAE Reporting is to be done online on the SUGAM portal as per the CDSCO order dated March 2021. Refer to Addendum SOP for SAE Reporting for details.

IV. Compensation- medical management and if related further compensation

Confidential

e
Dr Nithya Goktay
Professor & Head
Department of Clinical Pharmacology
1st Floor, MS Building
Seth GS Medical College & KEM Hospital
Parel, Mumbai 400 012

1-1-26

Page 5 of 9

Category : Study conduct-All studies (Government funded/NGO Regulatory)
Title : Serious Adverse Event (SAE) Monitoring, Recording and Reporting
SOP No/ Version No. : 15/08
Date first effective: 01 Jan 2026 **Review date:** 31 Dec 2026

Department of Clinical Pharmacology, 1st Floor, New MS Building,
 Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

4.1 Reimburse the participant for all expenses toward the medical management of the SAE in case of academic studies.

1.	Country (name of the country should be specified)	
----	---	--

4.2 In case of pharma sponsored studies, compensation to the participant will be provided by the sponsor as recommended by the Licensing authority.

4.3 If there is a clinical trial related death, the nominee will be contacted by the PI/ designated study team member for compensation as per regulatory rules.

V. Further steps

5.1 Various steps may be taken with respect to further use of the investigational product, comparator or placebo (in the interest of participant safety). This decision may only be made by the PI and will be as prescribed in the protocol, for example,

- Discontinue the investigational product, comparator, or placebo (Dechallenge)
- Reduce dose
- If necessary, for the immediate medical care of the participant, break the drug blind after consultation with the sponsor

7. Appendices:-

Appendix1: Table V for SAE Reporting


Dr Nithya Gogtay
 Professor & Head
 Department of Clinical Pharmacology
 1st Floor, MS Building
 Seth GS Medical College & KEM Hospital
 Parel, Mumbai 400 012

1-1-26

Category : Study conduct-All studies (Government funded/NGO Regulatory)
Title : Serious Adverse Event (SAE) Monitoring, Recording and Reporting
SOP No/ Version No. : 15/08
Date first effective: 01 Jan 2026 **Review date:** 31 Dec 2026

Department of Clinical Pharmacology, 1st Floor, New MS Building,
 Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

2.	SAE report of death or other than death	
3.	Patient details	
	Initials and other relevant identifier [hospital or outpatient department (OPD) record number etc]	
	Gender	
	Age or date of birth	
	Weight	
	Height	
4	Suspected Drug (s)	
	Generic name of the drug	
	Indication(s) for which suspect drug was prescribed or tested	
	Dosage form and strength	
	Daily dose and regimen (specific units- e.g., mg, ml, mg/kg)	
	Route of administration	
	Starting date and time of day	
	Stopping date and time, or duration of treatment	
5	Other treatment (s)	
	Provide the same information for concomitant drugs (including non-prescription or over the counter OTC drugs) and non-drug therapies, as for the suspected drug(s)	
6	Details of serious adverse events	
	Full description of the event including body site and severity as well as the criterion (or criteria) for considering the report as serious. In addition to a description of the reported sign and symptoms, whenever possible describe a specific diagnosis for the event	
	Start date (and time) of the onset of event	
	Stop date (and time) or duration of event	

Confidential

Dr Nithya Gogtay 1-1-26
 Professor & Head
 Department of Clinical Pharmacology
 1st Floor, MS Building
 Seth GS Medical College & KEM Hospital
 Parel, Mumbai 400 012

Page 7 of 9

Category : Study conduct-All studies (Government funded/NGO Regulatory)
Title : Serious Adverse Event (SAE) Monitoring, Recording and Reporting
SOP No/ Version No. : 15/08
Date first effective: 01 Jan 2026 **Review date:** 31 Dec 2026

Department of Clinical Pharmacology, 1st Floor, New MS Building,
 Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

	Dechallenge and rechallenge information	
	Setting (eg hospital, outpatient clinic, home, nursing home)	
7	Outcome:	
	Information on recovery and any sequelae; results of specific tests or treatment that may have been conducted	
	For a fatal outcome cause of death and a comment on its possible relationship to the suspected event. Any post-mortem findings	
	Other information: anything relevant to facilitate assessment of the case, such as medical history including allergy drug or alcohol abuse, family history, findings from special investigations etc.	
8	Details about the investigator*	
	Name and address	
	Telephone number	
	Profession (Specialty)	
	Date of reporting the event to Central Licensing Authority	
	Date of reporting the event to ethics committee overseeing the site:	
	Signature of the investigator or Sponsor	
	Note: Information marked * must be provided	

Dr Nithya Gogtay
 Professor & Head
 Department of Clinical Pharmacology
 1st Floor, MS Building
 Seth GS Medical College & KEM Hospital
 Parel, Mumbai 400 012

Category : Study conduct-All studies (Government funded/NGO Regulatory)
Title : Serious Adverse Event (SAE) Monitoring, Recording and Reporting
SOP No/ Version No. : 15/08
Date first effective: 01 Jan 2026 Review date: 31 Dec 2026

Department of Clinical Pharmacology, 1st Floor, New MS Building,
Seth GS Medical College & KEM Hospital, Parel, Mumbai 400012.

Appendix 2: IEC Checklist and Serious Adverse Event Report Assessment Form

SOP 11-B/V6.1 available at <https://www.kem.edu/sae-annexures>

Appendix 3: Timelines for reporting SAE

PI shall report all serious and unexpected adverse events to the Licensing Authority, the Sponsor or his representative and the Ethics Committee within 24 hours of their occurrence
PI shall be forwarded the report of the SAE, after due analysis, to the Licensing Authority, the Chairman of the Ethics Committee and the Head of the institution within 14 days of the occurrence
The Sponsor or his representative shall submit details of compensation provided or paid for clinical trial related injury or death, to the Licensing Authority within 30 days of the receipt of the order of the Licensing Authority

Reviewer as appropriate:

Signature with date

Roopa Parida
01/Jan/26

Dr. ROOPA PARIDA
Department of Clinical Pharmacology
Seth GS Medical College & KEM Hospital,
Parel, Mumbai-400 012.

Approved by Head of Department:

Dr. Nithya Gogtay
Professor and Head

Signature with date

Nithya Gogtay
1.1.26

Dr Nithya Gogtay
Professor & Head
Department of Clinical Pharmacology
1st Floor, MS Building
Seth GS Medical College & KEM Hospital
Parel, Mumbai 400 012

Confidential

Page 9 of 9

